Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2007

View Archived Issues

Recent patents describe new antidiabetic agents

Novel therapeutic options for obesity described in recent patent literature

Recent patents disclose novel antiinfective agents

Varenicline shows promise in preclinical models of alcohol dependence

CVBT-141F successfully completes preclinical stroke research

Pediatric phase II clinical trial of Intercell's JE vaccine begins in India

Opko Health initiates phase III trial of bevasiranib in wet AMD

Ghrelin receptor: Target To Watch for development of therapeutics for severe gastroparesis

Plethora secures funds for development of Invicorp for treatment of ED

Enrollment in Angiotech's CVC pivotal study completed

FDA approves initiation of phase III trials for Protalix's prGCD

Enrollment for CSL's phase III trial of subcutaneous immunoglobulin completed

H5N1 influenza antigen delivered to DelSite

Uluru and ImmuneRegen to codevelop wound care therapeutic

Update on Antisoma's phase II trial of ASA-404 for ovarian cancer

Positive results for Vernalis' phase IIa trial of V-3381 for neuropathic pain

YM reports secondary findings of phase IIb trial of AeroLEF for pain

FDA approves GeneSearch Breast Lymph Node Assay

Extina Foam approved for seborrheic dermatitis

First launch for Torisel

Ceftobiprole submissions accepted for review in U.S. and E.U.

Priority review for Abilify in treatment of major depressive disorder

VX-765 demonstrates antiseizure activity in animals

Studies reveal activity, pharmacokinetics of the antiepileptic eslicarbazepine

Studies profile lacosamide in epilepsy

Nerviano presents first Cdc7 kinase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...